Jim Simons Merus N.V. Transaction History

Renaissance Technologies LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$18.33 - $27.18 $257,004 - $381,090	14,021 New	14,021 $369,000
Q4 2022 Feb 13, 2023	SELL	$12.8 - $23.66 $327,680 - $605,696	-25,600 Reduced 35.46%	46,600 $721,000
Q3 2022 Nov 14, 2022	BUY	$18.64 - $28.93 $1.35 Million - $2.09 Million	72,200 New	72,200 $1.45 Million
Q1 2022 May 13, 2022	SELL	$23.58 - $30.91 $865,480 - $1.13 Million	-36,704 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$20.0 - $32.29 $255,440 - $412,407	-12,772 Reduced 25.81%	36,704 $1.17 Million
Q3 2021 Nov 12, 2021	SELL	$16.48 - $27.23 $689,671 - $1.14 Million	-41,849 Reduced 45.82%	49,476 $1.09 Million
Q2 2021 Aug 13, 2021	BUY	$20.0 - $25.48 $286,740 - $365,306	14,337 Added 18.62%	91,325 $1.92 Million
Q1 2021 May 13, 2021	BUY	$16.14 - $29.11 $842,314 - $1.52 Million	52,188 Added 210.44%	76,988 $1.61 Million
Q4 2020 Feb 10, 2021	BUY	$11.4 - $18.36 $282,720 - $455,328	24,800 New	24,800 $435,000
Q3 2020 Nov 13, 2020	SELL	$10.57 - $16.0 $157,493 - $238,400	-14,900 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$11.34 - $19.44 $26,082 - $44,712	-2,300 Reduced 13.37%	14,900 $180,000
Q4 2019 Feb 13, 2020	BUY	$14.08 - $18.5 $242,176 - $318,200	17,200 New	17,200 $242,000
Q3 2019 Nov 13, 2019	SELL	$14.55 - $20.52 $189,150 - $266,760	-13,000 Closed	0 $0
Q2 2019 Aug 12, 2019	SELL	$12.93 - $16.83 $38,790 - $50,489	-3,000 Reduced 18.75%	13,000 $190,000
Q1 2019 May 14, 2019	BUY	$11.09 - $15.83 $177,440 - $253,280	16,000 New	16,000 $236,000

200

61.9M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.28B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.